February 15th 2025
At the Envision Summit 2025 in San Juan, Puerto Rico, Jessica Steen, OD, FAAO talked with glaucoma surgeons on the importance of comanaging patients throughout their lifetime.
January 22nd 2025
December 31st 2024
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
CRU Eye Symposium
March 28-30, 2025
Register Now!
Eye Care Symposia in Los Angeles
April 25-26, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
19th Annual Controversies in Modern Eye Care
May 4, 2025
Register Now!
(CME Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(COPE Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (CME Track)
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (COPE Track)
View More
Collaborative Care Symposium
May 30-31, 2025
Register Now!
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)
View More
Burst CME Plus™ - Unveiling Pharmacological Advances in nAMD & DME: From Durability to Applicability
View More
Kill kinetics of advanced-generation fluoroquinolones compared in study
September 15th 2009An in vitro kill kinetics study evaluated eradication of 18 human ocular Staphylococcus isolates by commercial formulations of gatifloxacin 0.3% (Zymar, Allergan) and moxifloxacin 0.5% (Vigamox, Alcon Laboratories). Gatifloxacin demonstrated superior activity, which may be attributed to the presence of benzalkonium chloride 0.005% in its formulation.
Read More
Economic 'storms' can aid ophthalmologic practices in the future
September 15th 2009Now is the time to focus on the lessons that can be learned in the current economic situation. Take a close look at your staffing levels, practices within your office, and the effect of days spent out of clinic by physicians, among other things, to try to identify ways to weather bad economic times better in the future.
Read More
Analysis: Competency-based model to take over graduate medical education
September 15th 2009The apprenticeship model suffers from inherent limitations that have called into question not only the safety but the quality, appropriateness, and effectiveness of the training model for residents. External stakeholders in the educational process, including the public, the payers, and the government, have called for reform in the graduate medical education process and for transformation from the apprenticeship model to a competency-based model of education.
Read More
Sulcus placement of a proprietary three-piece multifocal IOL restores good outcome
September 15th 2009Sulcus placement of a proprietary three-piece multifocal IOL (ReZoom, Abbott Medical Optics) is a viable option in eyes in which capsular bag support is not adequate to ensure good lens stability. Then, if the lens decenters in the sulcus, scleral suturing is a safe and effective option for recentering the IOL and restoring good vision.
Read More
Fourth-generation fluoroquinolone widens the choice of antibiotic
September 15th 2009The introduction of a new fourth-generation fluoroquinolone for ophthalmic use may prompt an assessment of the pros and cons of the available agents. James P. McCulley, MD, explains his continued preference for moxifloxacin 0.5% (Vigamox, Alcon).
Read More
Diabetic macular edema responds to ranibizumab in study
September 15th 2009Diabetic macular edema responds to treatment with ranibizumab (Lucentis, Genentech), according to results of the RESOLVE study. The patient responses to the drug in the changes in the visual acuity and central macular thickness were significantly better in the groups treated with two concentrations of ranibizumab compared with the sham-treated group.
Read More
FDA resumes review of toric implantable contact lens
September 15th 2009The FDA will resume scientific review of the STAAR Surgical Co. premarket approval (PMA) application for its toric implantable contact lens ([TICL]; Visian Toric Implantable Collamer Lens) for patients with myopia and astigmatism after removing the "integrity hold" restrictions it put in place in 2007, according to the company.
Read More
DSEK shown to be safe, effective therapy, according to AAO cornea panel
September 8th 2009Descemet's stripping endothelial Keratoplasty (DSEK) was shown to be a safe and effective treatment for corneal endothelial diseases, according to a 2009 review by the cornea panel of the American Academy of Ophthalmology's (AAO) Ophthalmic Technology Assessment Committee, led by W. Barry Lee, MD.
Read More
Pfizer, Private Access aim to accelerate clinical research via online community
September 2nd 2009Pfizer has entered into a collaboration with Private Access to create a new online community aimed at increasing clinical trial awareness and participation. It will be rolled out in phases starting late this year.
Read More
Aton expands programs for preservative-free timolol
September 2nd 2009Aton Pharma has launched new education, distribution, sampling, and reimbursement programs for its preservative-free formulation of timolol maleate (Timoptic in Ocudose), which according to the company is the only preservative-free medication for glaucoma available in the United States.
Read More
STAAR Surgical reports progress on application to market products in Japan
September 2nd 2009STAAR Surgical Co. President and Chief Executive Officer Barry G. Caldwell said he is “encouraged and pleased” with feedback the company has received from the Japanese government regarding the possibility of marketing its implantable contact lens ([ICL] Visian Implantable Collamer Lens) products there.
Read More
Art exhibit focuses on macular degeneration
September 2nd 2009To mark the global observance of AMD [age-related macular degeneration] Week, Lighthouse International and AMD Alliance International (AMDAI) will host an exhibit of the works of London-based portrait artist Adam Hahn, whose paintings illustrate how patients with AMD see the world.
Read More
September is named by PBA as Home Eye Safety Awareness Month
September 1st 2009One in five at-home eye injuries are due to home repair or power tools according to results from the ?Sixth Annual Eye Injury Snapshot? by the American Academy of Ophthalmology and the American Society of Ocular Trauma.
Read More
Study: Sodium hyaluronate solution safe, effective
September 1st 2009An investigational compound for the treatment of dry eye disease consisting of a proprietary formulation of sodium hyaluronate ophthalmic solution 0.18% (Vismed, Lantibio Inc.) was shown to be safe and effective in a multicenter phase III trial conducted in the United States. A new drug application has been filed for the solution, which is already marketed in parts of Europe and Asia as a viscoelastic lubricant eye drop.
Read More
Don't go postal, go dental: remain aloof to organized medicine
September 1st 2009While ophthalmology has traveled down the road harnessed to organized medicine and thereby exposed to all of the exploding impediments to practice, dentistry has alertly remained aloof to these changes and continues to be viable, productive, and secure.
Read More
Vision care is lacking for children today
September 1st 2009Healthy vision is vital for success in life and should begin with regular vision screenings during childhood, but the level of inadequate vision care for children in the United States is significant, however. The author addresses ways to address this issue to positively affect high school graduation rates, social and emotional problems, juvenile delinquency, adult literacy problems, incarcerations, and workforce quality and productivity.
Read More
Glaucoma minishunt under scleral flap demonstrates long-term efficacy and safety
September 1st 2009A retrospective study analyzed outcomes of 345 consecutive eyes with the proprietary glaucoma minishunt (Ex-PRESS, Optonol) implanted, including 114 eyes having combined cataract surgery. During a mean follow-up of about 2 years, the implant provided effective IOP control whether used alone or in a combination procedure and was associated with few complications.
Read More
Preservative-free IOP-lowering medications of interest to ophthalmologists, survey finds
September 1st 2009Results of a survey of 124 ophthalmologists show interest in preservative-free formulations of IOP-lowering medications to preserve ocular surface health. Preservative-free timolol maleate (Timoptic in Ocudose, Aton Pharma) can be a good choice for appropriately selected patients, according to one ophthalmologist.
Read More
Glaucoma: Trabecular micro-bypass device aids IOP reduction in prospective study
September 1st 2009Implantation of a trabecular micro-bypass (iStent, Glaukos Corp.) in patients with open-angle glaucoma who are undergoing cataract surgery represents an alternative surgical approach that can provide clinically significant reductions in IOP and use of ocular hypotensive medications.
Read More
Endocyclophotocoagulation beneficial for those with glaucoma undergoing cataract surgery
September 1st 2009Endocyclophotocoagulation (ECP) can be performed easily in patients with medically controlled glaucoma who are undergoing cataract surgery, to provide additional IOP lowering and reduce medication use. Misunderstanding that ECP is a completely different procedure than transscleral cyclodestruction contributes to under-use of this very safe procedure, according to one ophthalmologist.
Read More
Glaucoma: Hyperemia a common cause for medication changes
September 1st 2009Hyperemia is one of the main reasons why patients with glaucoma do not adhere to or persist with their topical therapeutic regimen. Patients end up switching to another possibly more tolerable medication, and the changing of medications has significant financial implications. Latanoprost has the lowest incidence of hyperemia among the prostaglandin analogs. Patient adherence is crucial in a chronic progressive disease such as glaucoma, where non-adherence can lead to visual loss and decline in quality of life, creating societal health and economic burdens.
Read More